Clinical Trials Logo

Pseudoxanthoma Elasticum clinical trials

View clinical trials related to Pseudoxanthoma Elasticum.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06302439 Not yet recruiting - Clinical trials for ATP-Binding Cassette Subfamily C Member 6 Deficiency

PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

Start date: May 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes [PROs]) of each disease during routine, standard-of-care visits, with the aim of developing a comprehensive understanding of the burden of illness and progressive nature of the disease.

NCT ID: NCT05050669 Not yet recruiting - Clinical trials for Generalized Arterial Calcification of Infancy

Natural History Study of ENPP1 Deficiency and and the Early-onset Form of ABCC6 Deficiency

Start date: January 2022
Phase:
Study type: Observational

The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency (including Generalized Arterial Calcification of Infancy Type 1 [GACI] and Autosomal Recessive Hypophosphatemic Rickets Type 2 [ARHR2]) and the early-onset form of ABCC6 Deficiency (Generalized Arterial Calcification of Infancy Type 2 [GACI-2]) longitudinally.

NCT ID: NCT03364504 Not yet recruiting - Clinical trials for Pseudoxanthoma Elasticum

Biological Collection of Kidney Cells

CRHiPS
Start date: January 2018
Phase: N/A
Study type: Interventional

Our objective is to obtain human induced pluripotent stem cells from urine samples of PXE patients for further proteomic and metabolomic studies and treatment screening.